Publications

2012
101. Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes.
Tresilwised N, Pithayanukul P, Holm PS, Schillinger U, Plank C, Mykhaylyk O
Biomaterials. 2012 Jan .
PMID: 21978891 [PubMed - in process]
2011
102. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M, Boccaccio C, Comoglio P, Krüger A
Clin Exp Metastasis. 2011 Dec .
PMID: 21789719 [PubMed - in process]
103. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F, Napieralski R, Ulukaya E, Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M
Cell Biochem Funct. 2011 Dec .
PMID: 21887697 [PubMed - in process]
104. Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.
Klutz K, Willhauck MJ, Wunderlich N, Zach C, Anton M, Senekowitsch-Schmidtke R, Göke B, Spitzweg C
Hum Gene Ther. 2011 Nov .
PMID: 21488714 [PubMed - in process]
105. Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis.
Schwandt T, Schumak B, Gielen GH, Jüngerkes F, Schmidbauer P, Klocke K, Staratschek-Jox A, van Rooijen N, Kraal G, Ludwig-Portugall I, Franken L, Wehner S, Kalff JC, Weber O, Kirschning C, Coch C, Kalinke U, Wenzel J, Kurts C, Zawatzky R, Holzmann B, Layland L, Schultze JL, Burgdorf S, den Haan JM, Knolle PA, Limmer A
EMBO J. 2012 Jan 4.
PMID: 22036947 [PubMed - in process]
106. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Holzmüller R, Mantwill K, Haczek C, Rognoni E, Anton M, Kasajima A, Weichert W, Treue D, Lage H, Schuster T, Schlegel J, Gänsbacher B, Holm PS
Int J Cancer. 2011 Sep 1.
PMID: 21710499 [PubMed - in process]
107. Mechanisms balancing tolerance and immunity in the liver.
Böttcher JP, Knolle PA, Stabenow D
Dig Dis. 2011 .
PMID: 21894009 [PubMed - in process]
108. Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3.
Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, Debey-Pascher S, Knolle PA, Schultze JL
Clin Dev Immunol. 2011 .
PMID: 21904560 [PubMed - in process]
109. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.
Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP, Meister G
EMBO J. 2011 Oct 19.
PMID: 21857646
110. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation.
Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze JL
Nat Immunol. 2011 Sep .
PMID: 21841785